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angtj@cpu.edu.cnAbstract A selective precolumn derivatization liquid chromatography–tandem mass spectrometric
(LC–MS/MS) method for the determination of glucosamine in human plasma and urine has been
developed and validated. Glucosamine was derivatized by o-phthalaldehyde/3-mercaptopropionic
acid. Chromatographic separation was performed on a Phenomenex ODS column (150 mm 4.6
mm, 5 mm) using linear gradient elution by a mobile phase consisting of methanol (A), and an
aqueous solution containing 0.2% ammonium acetate and 0.1% formic acid (B) at a ﬂow rate of
1 mL/min. Tolterodine tartrate was used as the internal standard (IS). With protein precipitation
by acetonitrile and then the simple one-step derivatization, a sensitive bio-assay was achieved with
the lower limit of quantitation (LLOQ) as low as 12 ng/mL for plasma. The standard addition
calibration curves suitable for clinical sample analysis showed good linearity over the range of
0.012–8.27 mg/mL in plasma and 1.80–84.1 mg/mL in urine. The fully validated method has been
successfully applied to a pharmacokinetic study of compound glucosamine sulfate dispersible
tablets in health Chinese volunteers receiving single oral doses at 500, 1000 and 1500 mg of
glucosamine sulfate, as well as multiple oral doses of 500 mg t.i.d. for 7 consecutive days.
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1. Introduction
Glucosamine (2-amino-2-deoxy-D-glucose) is an amino sugar
and a prominent precursor involved in the biosynthesis of
glycosylated proteins and lipids, acting as a preferred substrate
for the biosynthesis of glycosaminoglycan chains, and subse-
quently, for the production of aggrecan and other proteogly-
cans of cartilage [1]. Glucosamine is believed to be effective in
easing osteoarthritis pain, rehabilitating cartilage, renewing
synovial ﬂuid and repairing joints that have been damaged
from osteoarthritis [2]. Hence, glucosamine is often prescribed
M. Song et al.20for the treatment of osteoarthritis [3]. Numerous nutraceutical
supplements as well as pharmaceutical preparations contain-
ing glucosamine as a single active component or combined
with other principles (such as chondroitin) are marketed
worldwide [4].
Because of the perceived beneﬁts and important clinical
application, the determination of glucosamine in human body
ﬂuids will give a further understanding of its action and make
the medication more effective and safe.
Many reports have been made about the bio-assay of
glucosamine directly or after derivatization. The direct detec-
tion methods were performed with normal chromatographic
separation in most cases [5–8]. However, there were a large
number of endogenous substances similar with glucosamine in
structure or polarity, such as glucose, galactosamine, amino
acids and peptides etc, in the bio-ﬂuids, having similar
retention behavior as glucosamine. Therefore, a long chroma-
tographic run time as long as 27 min [5,6] was necessary to
separate the strongly retained endogenous substances to
circumvent the matrix effects or interferences even with the
most selective MS/MS detection and to re-equilibrate the
column for repeated runs, which was inadequate for high
throughput analysis. Moreover, the use of a 13C labeled
glucosamine as the internal standard [5–8] was not sound
since there was only one atomic mass unit difference between
the analyte and the internal standard [9], the isotopic form of
the analyte would also contribute signiﬁcantly to the response
of the IS. Relatively quick separation was also achieved on
Cyano or Carbopack columns for underivatized glucosamine
in human plasma [10–12]. However, for the two anomeric
forms of glucosamine in equilibrium only one single peak was
recorded on the chromatograms. Therefore, the separation
might also suffer from endogenous interferences.
Several reversed-phase chromatographic methods were also
reported for the determination of glucosamine in bio-ﬂuids.
Meulyzer et al. [13] determined the glucosamine directly with
LC–MS on a C18 column (100 mm 2 mm, 5 mm). The
retention time of glucosamine and IS was only 2.4 min and
1.4 min, respectively. Although the short retentions had the
merits of high throughput, the unavoidable matrix effects
would affect the accuracy of determination [7].
In order to separate the glucosamine from endogenous polar
substances as much as possible, to improve the resolution and to
enhance the selectivity of glucosamine on reverse-phase chro-
matography, precolumn derivatization methods have been
developed for optimal and reproducible assay performances.
Phenylisothiocyanate (PITC) [14–17], 1-naphthyl isothiocyanate
[18], 9-ﬂuorenylmethyl chloroformate (FMOC-Cl) [19–21] and
6-aminoquinolyl-N-hydroxylsuccinimidyl carbamate (AQC)
[22,23] have been reported as derivative reagents for glucosa-
mine. Since the samples are often of large number in bio-study,
the derivatization method should be as simple and rapid as
possible. However, the PITC [14–16] includes steps of removing
the excess of derivative reagent and drying the samples under
vacuum. The AQC [22] has steps of separating the aqueous layer
from the organic for the derivatization. For FMOC-Cl and 1-
naphthyl isothiocyanate, the derivative products are unstable,
and the buffer concentration will give marked inﬂuences on the
reaction [21,23]. In addition, the sensitivity of the derivative
methods [14–23] was not appropriate for human bio-ﬂuids in
most cases for the best LOD achieved among them was only
15 ng/mL [19].In this study, a precolumn derivatization LC–MS/MS
method was developed and fully validated for the quantitation
of glucosamine in human plasma and urine. O-phthalalde-
hyde/3-mercaptopropionic acid (OPA/3-MPA) was used as
the derivative reagent which is remarkable for its simple
derivative procedures [24–27]. The signiﬁcantly improved
chromatographic retention and separation behavior post the
derivatization, and the highly selective and sensitive detection
afforded by the MS/MS selective reaction monitoring have
made the LLOQ of the method as low as 12 ng/mL in human
plasma. The method was successfully applied to a pharmaco-
kinetic study of compound glucosamine sulfate dispersible
tablet in healthy Chinese volunteers receiving single oral doses
at 500, 1000 and 1500 mg of glucosamine sulfate, as well as
multiple oral doses of 500 mg t.i.d. for 7 consecutive days.2. Experimental
2.1. Chemicals and reagents
Compound glucosamine sulfate dispersible tablets (each con-
tains 250 mg glucosamine sulfate and 200 mg chondroitin
sulfate, Lot No.: 071201) was supplied by the Guangzhou
Yipinhong Pharmaceutical group Co. Ltd. (Ghangzhou, China).
The chemical reference standards of glucosamine hydrochloride
(499.8% purity) and tolterodine tartrate (IS) (499.8% purity)
were purchased from the National Institute for the Control of
Pharmaceutical and Biological Products (Beijing, PR China).
HPLC-grade methanol was the product of Tedia Company Inc.
(Fairﬁeld, OH, USA). Formic acid, ammonium acetate, sodium
tetraborate, o-phthalaldehyde (OPA) and 3-mercaptopropionic
acid (3-MPA) were all of analytical grade obtained from
Nanjing Chemical Reagent Company Inc. (Nanjing, PR China).
Water was prepared with double distillation.
2.2. Instrumentation
The LC–MS/MS system consisted of a Thermo-Finnigan TSQ
Quantum Ultra AM tandem mass spectrometer equipped with
an ESI source (San Jose, CA, USA), a Surveyor LC pump and a
Surveyor auto-sampler. The system control and data acquisition
were performed with Xcalibur 1.2 software (Thermo-Finnigan,
San Jose, CA, USA). Peak integration and calibration were
carried out using LC Quan software (Thermo-Finnigan).
2.3. Preparation of derivative reagent
The derivative reagent was prepared by dissolving 50 mg of
anhydrous OPA with 1 mL of methanol, and then mixing
thoroughly with 10 mL of 0.05 mol/L borate buffer (pH 9.3)
and 0.1 mL 3-MPA. The solution was freshly prepared and
kept at 4 1C on daily basis and no signs of deterioration were
observed within this period.
2.4. Calibration standards and quality control samples in
human plasma and urine
Endogenous level of glucosamine in human plasma was found
to be 10 –200 ng/mL [8]. Therefore, the pooled human blank
plasma was used for the preparation of calibration standards
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determined before use by standard addition calibration with
linear regression of a series of spiked standards. Then the
actual concentration of calibration standard was deﬁned as the
sum of the endogenous and the spiked concentration. The
actual concentration as free base was used hereafter unless
indicated otherwise. The blank urine was collected from a
volunteer after two day bland diet.
Glucosamine hydrochloride stock solution of 1 mg/mL was
prepared in distilled water. The working solutions with
concentrations in the range of 0.1–80 mg/mL for plasma and
4–800 mg/mL for urine were prepared by serial dilution of the
stock solution with water. The IS solutions of 0.4 and 2 mg/mL
were prepared similarly for the determination of glucosamine
in plasma and urine, respectively. All the stock and working
solutions were prepared in brown volumetric ﬂasks, stored
shaded from light at 4 1C and used within one week.
The standard addition calibration plasma samples
were prepared by spiking aliquots of 0.4 mL of the pooled
blank human plasma (the glucosamine concentration was
estimated to be 3.8 ng/mL) with 40 mL of the corresponding
working solutions, respectively to yield concentrations
of 0.012, 0.020, 0.037, 0.087, 0.169, 0.417, 0.831, 1.66, 4.14
and 8.27 mg/mL. The calibration urine samples of 1.80, 2.21,
3.04, 5.52, 9.65, 17.9, 42.7 and 84.1 mg/mL were prepared
similarly with blank human urine (the glucosamine concentra-
tion was estimated to be 1.4 mg/mL). The QC samples were
0.020, 0.169 and 1.66 mg/mL in plasma and 2.21, 9.65 and
42.7 mg/mL in urine. All the samples were stored at 20 1C
until analysis.2.5. Sample preparation and derivatization
For plasma sample, an aliquot of 0.4 mL plasma in a 2 mL
Eppendorf tube was mixed with 40 mL water (except for the
calibration and QC standards), 40 mL IS solution (0.4 mg/mL
tolterodine tartrate in water) and 0.8 mL acetonitrile by
vortex-mixing for 1 min to free the analyte and precipitate
protein. 150 mL of the supernatant obtained after centrifuging
at 16,000g for 10 min at 5 1C was transferred into an auto-
sampler vial, then mixed with 0.35 mL of 0.05 mol/L borate
buffer (pH 9.3) and 0.15 mL of derivative reagent to carry out
the derivatization at 25 1C water bath for 15 min under dim
light. Then the resultant solution was kept refrigerated at
20 1C before 25 mL was injected into the LC–MS/MS system
for analysis within 8 h. The derivatization reaction of gluco-
samine with OPA/3-MPA is shown in Fig. 1.
The urine sample was processed in the same manner as
plasma described above except that the 2 mg/mL tolterodine
tartrate was used as the IS solution.Figure 1 The derivatization reaction2.6. Chromatography and mass spectrometry condition
Liquid chromatography was performed on a Phenomenex ODS
column (150 mm 4.6 mm, 5 mm) preceded by an ODS guard
cartridge (2 mm 4 mm). The mobile phase consisted of metha-
nol (A) and an aqueous solution containing 0.2% ammonium
acetate and 0.1% formic acid (B) pumped at a ﬂow rate of
1 mL/min with the following steep linear gradient elution steps:
0.0 min (45%A–55%B)-1.0 min (45%A–55%B)-2.5 min
(95%A–5%B)-4.9 min (95%A–5%B)-5.0 min (45%A–
55%B)-6.5 min (45%A–55%B). The auto-sampler tray tem-
perature was set at 4 1C for the optimal sample stability.
To avoid excessive entry of complex endogenous compo-
nents into the MS system, only 30% of the eluent was split
into the inlet of the ESI probe of the mass spectrometer and
the ﬂow was directed into the instrument only during the
window time for the target compounds analysis, after 2.8 min
of each chromatographic run.
The MS/MS detections were performed with positive ion
ESI and selected reaction monitoring. The spray voltage,
heated capillary temperature, nitrogen sheath and auxiliary
gases were optimized and set at 5 kV, 350 1C, 275 kPa and
70 kPa, respectively. The argon gas collision induced dissocia-
tions were used with a pressure of 0.20 Pa and collision energy
of 35 eV for both glucosamine derivatives and IS. Their
product ion-scan spectra are shown in Fig. 2. The most stable
and strongest ion transitions were selected for the quantitation
of glucosamine with m/z 384-118 for the glucosamine-OPA/
3-MPA derivatives and m/z 326-147 for IS. The run time for
each LC–MS/MS analysis was 6.5 min.2.7. Method validation
The method validation was carried out according to the guide-
lines for bio-assay of the U.S. Food and Drug Administration
(FDA) [28], including speciﬁcity, matrix effect, precision, accu-
racy, linearity, sensitivity, extraction recovery and stability.
The speciﬁcity of this assay was investigated by analyzing
six individual human blank plasma and urine samples.
The matrix effect was evaluated by comparing the chroma-
tographic peak areas of the analyte from the spike-after
protein precipitation samples with the neat standards in
duplicates at the QC concentrations.
Bio-samples were quantitated using the peak area ratios of the
analyte to the IS. The calibration curves were established through
a linear least squares regression with a weighting factor of 1/C2,
where C is the concentration of the calibration standards. The
criteria for the calibration include a correlation coefﬁcient (r) of
0.996 or better, and the deviation of the found from the nominal
being within 715% except for LLOQ of 720%.of glucosamine with OPA/3-MPA.
Figure 2 The product ion spectra and proposed fragmentation processes of glucosamine-OPA/3-MPA derivatives (A) and IS (B).
M. Song et al.22The extraction recoveries was determined by comparing the
responses of the analyte extracted from quintuplicate QC
samples with the responses of the analyte spiked after protein
precipitation samples at an equivalent concentration.
The precision and accuracy of the method were evaluated
by analyzing quintuplicate samples at three QC concentration
levels and assessed by within- and between-batch validation.
The acceptance criteria for within- and between-batch preci-
sion (expressed as relative standard deviation, RSD%) were
720% for LLOQ and 715% for the other concentrations.
For accuracy, the acceptance criteria were 100720% for
LLOQ and 100715% for the other concentrations.
Post-preparative stability of the processed samples, i.e. the
stability of derivative products, was investigated carefully,
including the residence time in auto-sampler tray at 4 1C and
refrigerator at 20 1C for 24 h.
Stability of glucosamine in plasma and urine samples under
different storage and processing conditions were evaluated
after the stability of the glucosamine-OPA/3-MPA derivatives
were thoroughly established. QC samples of low and high
concentration, 0.020 and 1.66 mg/mL for plasma, 2.21 and
42.7 mg/mL for urine, were used for the stability evaluation.
Freeze-thaw stability samples were stored at 20 1C for
24 h and thawed unassisted at room temperature. When
completely thawed, the samples were refrozen for 12 h under
the same condition and the freeze-thaw cycles were repeated
up to three times. Freeze-thaw samples were then analyzed
with comparison to the freshly prepared references.
Short-term stability was determined by analyzing QC samples
kept at room temperature for 8 h. To investigate long-term
stability, samples were kept at 20 1C for up to 60 days.2.8. Application to pharmacokinetic study
The established method was applied to a pharmacokinetic
study of compound glucosamine sulfate dispersible tablets with
an open-label, randomized, parallel-group design. Thirty
healthy Chinese volunteers (15 males and 15 females) with
mean age 34.873.3 years, mean weight 58.774.3 kg and mean
height 164.176.8 cm, were randomized into three parallel-groups (5 men and 5 women in each group), who received a
single oral dose of 500, 1000 and 1500 mg (the dose was
expressed as glucosamine sulfate) with 250 mL of water after
an overnight fast. Venous blood samples about 3.5 mL were
drawn before administration (0 h) and after 0.5, 1.0, 1.5, 2.0,
2.5, 3.0, 4.0, 5.0, 6.0, 8.0, 10, 12, 14 and 24 h in heparinized
tubes. The plasma samples were obtained by centrifuged at
1000g force for 10 min. Urine samples of the 1000 mg dose
group were collected before (0 h) and after administration for
time segments of 0–3, 3–6, 6–10, 10–14 and 14–24 h. The
500 mg group was continued to be given multiple oral doses of
500 mg t.i.d. for 7 consecutive days, and the steady-state was
evaluated by blood sampling before morning doses on day 4
through 7 and at the same time points as those after a single
oral dose on day 7. The separated plasma and urine samples
were all stored at 20 1C until analysis. The study was
conducted at Xijing hospital. The study protocol was approved
by the local Ethical Review Committee in accordance with the
principles of the Declaration of Helsinki, and the recommen-
dations of the State Food and Drug Administration of China.
Written informed consent was obtained from all subjects. All
the subjects were instructed to abstain from taking any
medication for 2 weeks before and during the whole study
period unless otherwise deemed as necessary by the doctor.
The maximum observed plasma concentration (Cmax) and
the time of its occurrence (Tmax) were obtained directly from
the concentration–time curve. Other pharmacokinetic para-
meters were calculated by non-compartmental method and
statistical analysis was performed using the DAS program
(Drugs and Statistics version 2.0, Chinese Pharmacological
Society, China). Analysis of variance (ANOVA) was used to
assess the gender or treatment group differences. Po0.05 was
taken as statistically signiﬁcant in all tests.3. Results and discussion
3.1. LC–MS/MS condition
The reversed phase HPLC and volatile mobile phase were
chosen based on the physicochemical properties of the analyte
LC–MS/MS method for the determination and pharmacokinetic study of glucosamine 23and characteristics of MS detection. Various types and brands
of analytical column (C18, C8 and PFP) and mobile phase
compositions were evaluated. It was found that the retention
behaviors of the glucosamine derivatives and the IS were
inﬂuenced signiﬁcantly by the pH and composition of the
mobile phase (methanol, ammonium acetate, formic acid or
acetic acid in water). In the pH range of 2.0–7.5 tested, the
lower pH tends to give a better retention and sharper peaks
for the glucosamine-OPA/3-MPA derivatives. However, the
peak of the IS became broad and asymmetric when the pH of
the mobile phase was below 3.0, such as the mixture of 50
volumes of 0.2% formic acid in water and 50 volumes of
methanol. Finally sharp chromatographic peaks with suitable
retention time for both analyte and IS were obtained using a
mixture of methanol (A) and an aqueous solution containing
0.2% ammonium acetate and 0.1% formic acid (B) as mobile
phase with the following steep linear gradient elution steps:
0.0 min (45%A–55%B)-1.0 min (45%A–55%B)-2.5 min
(95%A–5%B)-4.9 min (95%A–5%B)-5.0 min (45%A–
55%B)-6.5 min (45%A–55%B).Figure 3 Representative chromatograms of (A) the blank plasma sa
glucosamine and (C) a plasma sample from a healthy volunteer 2 h a
dispersible tablets. The retention time for the two glucosamine derivaMoreover, glucosamine is present with two anomeric forms
in equilibrium [23]. Therefore two peaks are found on the
chromatogram (Figs. 3 and 4) with retention time of 3.2 and
4.1 min for the corresponding glucosamine-OPA/3-MPA deri-
vatives. The area sum of these two peaks was handled together
for the quantitation.
Triple quadrupole tandem mass spectrometry has great
advantage in reducing interferences and enhancing sensitivity
over other MS detection methods [29]. The mass detection was
carried out with positive electrospray ionization and SRM.
Parameters such as the spray voltage, capillary temperature,
desolvation nitrogen gas ﬂows were tuned to maximize the
speciﬁcity and sensitivity for the detection. What is more, the
argon gas collision induced dissociation behaviors of both
compounds concerned were strongly dependent on the gas
pressure and collision energy. The product scan spectra are
shown in Fig. 2. The most stable SRM transition was selected
with m/z 384-118 for glucosamine derivatives and m/z 326-
147 for IS accordingly with the argon gas pressure and
collision energy set at 0.2 Pa and 35 eV, respectively.mple, (B) a calibration standard of plasma sample 0.169 mg/mL
fter oral administration of 500 mg compound glucosamine sulfate
tives and IS is 3.2, 4.1 and 5.2 min, respectively.
Figure 4 Representative chromatograms of (A) the blank urine, (B) a calibration standard of urine sample 9.65 mg/mL of glucosamine
and (C) a urine sample from a healthy volunteer 3–6 h after oral administration of 1000 mg compound glucosamine sulfate dispersible
tablets. The retention time for the two glucosamine derivatives and IS is 3.2, 4.1 and 5.2 min, respectively.
M. Song et al.243.2. Sample preparation and derivatization
A simple protein precipitation was used for sample pretreat-
ment based on the high polarity, intrinsic stability and freely
water solubility of glucosamine. Acetonitrile was found to give
best results with regard to the recovery and derivatization for
both plasma and urine samples.
The key point of this study was to establish an optimal
derivatization method to improve the retention, which could
overcome the matrix effects and enhance the sensitivity and
selectivity of glucosamine. The method should be also as
rugged and simple as possible to meet the demand of high
throughput clinical bio-assay. Among the common derivate
reagents for amino compounds, such as PITC, FMOC-CL,
naphthyl or phenylisothiocyanate, OPA, AQC, Dabsyl-Cl and
Dansyl-C1, OPA is remarkable for its water compatibility and
simplicity [24–27].
The OPA/3-MPA combination was used for the derivatiza-
tion of glucosamine. And three main factors were investigatedto improve derivative yield. They were the amount of the
derivative reagent, reaction temperature and reaction time as
well. The optimization was conducted for plasma and urine
samples. The optimum results revealed that the derivative
conditions were almost the same for these two types of
samples with a reagent volume of 0.15 mL, reaction tempera-
ture at 25 1C for 15 min.
However, the OPA derivatives of some amino compounds
tend to have relatively poor stability [24,25]. Therefore, the
stability of glucosamine-OPA derivatives was investigated in
great detail at the very beginning of this study. The stabi-
lity test results demonstrated that both plasma and urine
sample derivatives did not show obvious degradation under
cool places, i.e. the deviations were less than 10% in auto-
sampler tray at 4 1C and in the refrigerator at 20 1C for 12
and 24 h. Therefore, all the derivatized samples were kept
frozen at 20 1C immediately after the derivative reaction and
the LC–MS/MS analysis was carried out within 8 h in order to
guarantee the suitability and accuracy of the determination.
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The selection of internal reference standard is an important
part for accurate and precise LC–MS/MS analysis of bio-
samples. Primary amino group containing compounds, which
could also react with the OPA/3-MPA, such as tranexamic
acid, fudosteine, ganciclovir and penciclovir were investigated
at ﬁrst. For they all have similar physicochemical properties as
glucosamine except for amino acids, which would suffer from
endogenous interferences. However the intrinsic poor stability
of the derivatives of these compounds and the obvious
differences between them made these internal standard candi-
dates no contribution.
The use of stable isotope labeled analogs as internal
standard is always highly recommended for MS detection
since the inﬂuences of matrix effects and differences of
ionization efﬁcacies would all be eliminated. Though, pro-
blems such as cross-talk between MS channels and isotopic
purity should also be carefully addressed. But there was no
commercially available multiply stable isotope labeled gluco-
samine for bio-analysis [10].
Finally, tolterodine tartrate, a tertiary amine group contain-
ing compound, was chosen as the internal standard. Because it
was stable and easily recovered at the protein precipitation
and derivatization processes, and it worked as a good
indicator for the recovery and stability of glucosamine. More-
over, the similar chromatographic and mass spectrometric
features with the glucosamine-OPA/3-MPA derivatives made
tolterodine tartrate an eligible internal standard here.
3.4. Method validation
3.4.1. Speciﬁcity and matrix effects
Due to the endogenous glucosamine and the highly sensitive
method, there is no glucosamine free blank plasma and urine.
Therefore, the blank plasma and urine samples were prepared
and assayed in advance for the preparation of calibration and
QC standards. The mean endogenous concentrations of
glucosamine in the blank plasma and urine used were found
to be about 3.8 ng/mL and 1 mg/mL, respectively. At the same
time, the blank plasma and urine did not show any interfer-
ences of IS. The retention time of the two glucosamine
derivatives and IS was 3.2, 4.1 and 5.2 min, respectively.
Typical chromatograms of plasma and urine samples are
shown in Figs. 3 and 4, respectively.
Matrix effect values in the plasma and urine were varied
from 87.6% to 103.2% and 94.1% to 118.7%, respectively,Table 1 Within- and between-batch precision and accuracy for g
Sample Conc.
(mg/mL)
Within-batch (n¼5)
Mean conc.
found (mg/mL)
Accuracy (%) RS
Plasma 0.020 0.02470.001 120.0 4.1
0.169 0.16070.005 94.7 3.1
1.66 1.58070.058 95.2 3.6
Urine 2.21 2.1370.10 96.4 4.6
9.65 10.1070.47 104.7 4.6
42.7 47.3070.96 110.8 2.0which were all within the acceptable limits. The same evalua-
tion was performed on the IS. There was no signiﬁcant ion
suppression or enhancement for the targeted ions, which
ensured the accuracy and precision of the assay.3.4.2. Linearity and LLOQ
The method showed good linear response over the glucosa-
mine concentration range of 0.012–8.27 mg/mL for plasma
and 1.80–84.1 mg/mL for urine. Typical calibration curves
were Y¼0.9798C0.0014 with r¼0.998 in plasma, and
Y¼0.3365Cþ0.3660 with r¼0.999 in urine, where Y is the
peak area ratio of the analyte to IS and C is the concentration
of the glucosamine. Because of the high endogenous glucosa-
mine level in the blank plasma and urine, the lower limit of
quantitation (LLOQ) was set at 12 ng/mL for plasma and
1.80 mg/mL for urine. The LOD of the method might have
been driven much lower.3.4.3. Accuracy, precision and extraction recovery
The within- and between-batch accuracy and precision data
are summarized in Table 1. They were within the limits of
acceptance criteria set by the guidelines for bioanalytical
methods validation [28].
Extraction recoveries as shown in Table 2 were found to be
all over 85% at all the QC levels for both plasma and urine
samples with acceptable deviation.3.4.4. Stability
The glucosamine-OPA derivatives were found to be stable and
no signiﬁcant degradation within 24 h when kept at 4 1C or
20 1C (RSDo10%). However, due to intrinsic instability of
the OPA derivatives of amino carbohydrates, all the processed
samples were immediately put into a 20 1C refrigerator and
kept at that status for no more than 24 h before the LC–MS/
MS determination. The residence time of the sample in the
auto-sampler tray prior to the analysis was managed to be less
than 8 h.
The stability test results of glucosamine in plasma and urine
under different storage conditions investigated showed that
they were stable after three freeze-thaw cycles, a short-term of
8 h bench-top duration and a long-term storage at 20 1C up
to 2 months, since no signiﬁcant degradations were observed
in all the cases for the deviations in the concentrations tested
were all within 10% of their nominal values with RSDo15%.
The stability data pertaining to glucosamine in human plasma
and urine are summarized in Table 3.lucosamine in plasma and urine (mean7SD).
Between-batch (n¼15)
D (%) Mean conc.
found (mg/mL)
Accuracy (%) RSD (%)
7 0.02270.002 110.0 9.09
3 0.17270.012 101.8 6.98
7 1.66070.009 100.0 5.42
9 2.1470.18 96.8 8.41
5 9.8270.40 101.7 4.07
3 45.9072.01 107.5 4.38
Table 2 Extraction recovery of glucosamine in plasma and urine (mean7SD, n¼5).
Sample Conc. (mg/mL) Mean conc. found (mg/mL) Mean recovery (%)
Plasma 0.020 0.01870.001 90.0
0.169 0.18070.009 106.5
1.660 1.65870.078 99.9
Urine 2.21 1.9670.09 93.3
9.65 9.6970.50 100.4
42.7 46.1273.07 108.5
Table 3 Stability data pertaining to glucosamine in human plasma and urine (mean7SD, n¼2).
Storage conditions Plasma Urine
Conc.
(mg/mL)
Mean conc.
found (mg/mL)
Accuracy
(%)
Conc.
(mg/mL)
Mean conc.
found (mg/mL)
Accuracy
(%)
Derivatives at 4 1C for 24 h 0.020 0.02370.001 115.0 2.21 1.8170.04 81.9
1.660 1.77670.020 117.7 42.7 39.8071.96 93.2
Derivatives at 20 1C for 24 h 0.020 0.02270.002 110.0 2.21 2.1670.04 97.4
1.660 1.68570.073 101.5 42.7 42.4071.01 99.3
Freeze-thaw (n¼3) 0.020 0.02070.002 100.0 2.21 2.3670.09 106.6
1.660 1.74770.037 105.2 42.7 45.0074.29 105.3
Short-term after 8 h (25 1C) 0.020 0.02370.002 115.0 2.21 2.3170.08 104.2
1.660 1.63370.285 98.4 42.7 47.5071.60 111.2
Long-term after 60 d (20 1C) 0.020 0.01870.001 90.0 2.21 2.2070.20 99.2
1.660 1.77070.099 106.6 42.7 44.3074.10 103.7
Figure 5 Mean (7SD) plasma concentration–time proﬁles of
glucosamine in healthy Chinese volunteers (n¼10) after a single
oral administration of 500, 1000 and 1500 mg and after multiple
doses of 500 mg t.i.d. on the 7th day to healthy volunteers.
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The plasma glucosamine baseline levels found in the recruited
Chinese volunteers were in the range of 0–120 ng/mL with a
mean of 16.7726.9 ng/mL (n¼30), and urine glucosamine
levels were in the range of 2.79–8.07 mg/mL with a mean of
4.9671.74 mg/mL (n¼10). The plasma glucosamine baseline
levels found in the Chinese volunteers were much lower than
those in the Caucasian volunteers reported by Persiani [8],
which ranged from 10.4 to 204.0 ng/mL with a mean value of
45.3 ng/mL. These might be due to the racial and food
differences between the subjects.
The validated LC–MS/MS method was successfully applied
to a pharmacokinetic study of compound glucosamine sulfate
dispersible tablets in healthy Chinese volunteers after single
oral doses of 500, 1000 or 1500 mg, as well as multiple oral
doses of 500 mg t.i.d. for 7 consecutive days. The mean plasma
glucosamine concentration–time proﬁles are shown in Fig. 5.
The main pharmacokinetic parameters are presented in
Table 4. It was shown that glucosamine was rapidly absorbed
and the peak concentration was reached at about 2 h after oral
administration. The plasma glucosamine was eliminated to the
baseline level at about 10 h post-dosing. Therefore, faster
excretion was found in Chinese than Caucasian volunteers [8].
The main pharmacokinetic parameters (Tmax, MRT and t1/2)
did not show any statistical difference (P40.05) at the three
dose levels as well as gender differences (P40.05). While the
dose-normalized values of the area under plasma concentration–
time curves (AUC), the mean peak concentrations (Cmax) for the1500 mg dose group were both signiﬁcantly lower than the
corresponding values calculated at the 500 and 1000 mg dose
groups (Po0.05). Therefore, a non-linear absorption at higher
doses was obvious with oral administration. This may be due to
Table 4 The pharmacokinetic parameters for glucosamine after single oral doses of 500, 1000, 1500 mg and after multiple doses
of 500 mg t.i.d. on the 7th day to healthy volunteers (mean7SD, n¼10).
Parameters 500 mg 1000 mg 1500 mg Multiple-dose
Cmax (mg/mL) 0.41770.190 0.79570.280 0.92570.280 0.29470.076
Tmax (h) 2.6071.39 2.7070.86 1.9070.84 1.9071.10
AUC0–10 (mg h/mL) 1.4270.20 3.3771.02 4.0371.28 1.0270.24
AUC0–N (mg h/mL) 1.4370.21 3.4271.01 4.1871.40 1.0270.24
MRT0–10 (h) 3.1870.71 3.5770.24 3.3070.61 2.7070.34
t1/2 (h) 1.1770.40 1.3270.35 1.3670.94 1.4170.76
CL/F (mL/h) 0.28070.042 0.24570.061 0.32170.140 0.40770.120
Css_min (mg/mL) – – – 0.05970.056
Css_av (mg/mL) – – – 0.12570.031
AUCss (mg/mL h) – – – 1.0070.24
DF (%) – – – 1.9070.93
Table 5 Urine excretion (% of dose) of glucosamine after
single oral dose of 1000 mg to healthy volunteers
(mean7SD, n¼10).
Time after dosing (h) Urine excretion (%)
0–3 0.43470.300
0–6 1.3971.45
0–10 1.8371.84
0–14 1.9071.86
0–24 1.9971.86
LC–MS/MS method for the determination and pharmacokinetic study of glucosamine 27a saturation of the absorption process, which was also evinced
by the higher CL/F values observed at the 1500 mg dose group.
The same non-linear absorption phenomenon was also found in
the Caucasian subjects [8].
The pharmacokinetic parameters of glucosamine after
multiple oral doses of 500 mg compound glucosamine sulfate
dispersible tablets t.i.d. for 7 consecutive days were similar
with those after a single-dose. Therefore, no signiﬁcant
accumulation effects were seen in Chinese subjects. This was
due to the short elimination half-life time observed.
The urinary excretion (% of dose) of glucosamine after
single oral dose of 1000 mg compound glucosamine sulfate
dispersible tablets is shown in Table 5. The excretion was
almost completed in the ﬁrst 10 h after the oral administration
with no statistically signiﬁcant gender differences (P40.05).4. Conclusion
The established precolumn derivatization LC–MS/MS method
improved the chromatographic retention and reduced the
matrix effects signiﬁcantly, which made the LLOQ down to
12 ng/mL for human plasma. The robust acetonitrile protein
precipitation in combination with a rapid OPA/3-MPA
derivatization also simpliﬁed the sample pretreatment pro-
cesses signiﬁcantly, which was very important for clinical
investigation. Meanwhile, the good stability of the derivatives
of glucosamine in the auto-sampler tray at 4 1C and in the
refrigerator at 20 1C within 24 h made the determination
feasible. These characteristics of the precolumn derivatization
LC–MS/MS method guaranteed the sensitive, speciﬁc and
accurate determination of glucosamine in bio-ﬂuids. The fullyvalidated method has been successfully applied to the phar-
macokinetics in health Chinese volunteers.References
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